abstract: @entity4039 ( @entity4039 ) mainly occurs in pubertal @entity1 and is associated with delayed skeletal maturation, @entity28 , high growth velocity and tall stature. Furthermore, @entity4039 often coincides with @entity4903 . This is the first report of a possible relationship between @entity4039 and @entity1176 agonist treatment: four @entity1 developed @entity4039 during or shortly after treatment with @entity1176 agonists was stopped. We compared the clinical aspects of these @entity1 with @entity1 described in the literature who developed @entity4039 . Puberty started at the age of 3.3, 9.6, 0.0 and 5.6 years respectively. One @entity1 developed sequential @entity4039 of both hips. @entity4039 occurred at the age of 11.9 ( @entity1 1), 12.7 ( @entity1 2), 14.3 ( @entity1 2), 11.3 ( @entity1 3) and 11.3 ( @entity1 4) years. Of the five incidences of @entity4039 , one occurred during @entity1176 agonist treatment and four shortly after treatment was stopped. None of our @entity1 met the typical criteria seen in @entity4039 and no 'regular' characteristics of @entity1 with @entity4039 could be designated. Probably the hormonal changes during and shortly after treatment with @entity1176 agonists make the epiphysis more prone to slip. Considering our observations and by reviewing the literature, @entity1176 agonist treatment might present a risk factor for the occurrence of @entity4039 .

title: Can XXXX -agonist treatment cause slipped @entity4039 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity4039 :: ('MESH:D060048', 'Disease') :: ['Slipped capital femoral epiphysis', 'SCFE']

entities_list: @entity4903 :: ('MESH:D004700', 'Disease') :: ['endocrine disorders']

answer: @entity1176 :: (MESH:D007987,Chemical) :: ['GnRH']


abstract: OBJECTIVE: To explore the efficacy and mechanism of hemoperfusion (HP) plus hemodialysis (HD) for @entity1897 of @entity1381 @entity1 on maintenance hemodialysis. METHODS: A total of 66 @entity1381 @entity1 on hemodialysis during January 2014 and April 2011 were assigned randomly into HP + HD, @entity258 and high-flux HD groups (n = 22 each). The serum levels of leptin, @entity2232 ( @entity2232 ), @entity461 ( @entity461 ) and @entity6393 were observed pre and post-treatment. And sensory conduction velocity ( @entity6723 ) was detected simultaneously. RESULTS: After 12-week treatment, the clinical symptoms of group HP + HD improved significantly with an effective rate of 90.91% while improvement was not obvious in groups high-flux and @entity258 with effective rates of 31.82% and 13.64%. In HP + HD group, the levels of leptin, @entity2232 , @entity461 and b-2MG decreased, sensory conduction velocity increased (P < 0.05) and clinical symptoms improved apparently. While in @entity258 and high-flux HD groups, leptin, @entity2232 , @entity461 and b-2MG had no decrease and @entity6723 showed no improvement (P > 0.05). Correlation analysis showed that the levels of leptin, @entity2232 and b-2MG were negatively correlated with @entity6723 (r = -0.57, r = -0.47, r = -0.56). Yet @entity461 had no correlation with @entity6723 (r = -0.23). CONCLUSION: Hemoperfusion plus hemodialysis may improve the clinical symptoms of @entity1897 of @entity1381 @entity1 on maintenance hemodialysis. And it is probably due to the fact that HP + HD effectively removes such plasma middle and macromolecular toxins as leptin, @entity2232 , @entity461 and b-2MG.

title: [Efficacy and mechanism of hemoperfusion plus hemodialysis for @entity1897 of XXXX @entity1 on maintenance hemodialysis].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['low-flux HD']

entities_list: @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone']

answer: @entity1381 :: (MESH:D006463,Disease) :: ['uremic']


abstract: The aim of this study was to investigate the role of the complement regulatory protein cluster of differentiation  55 ( @entity18544 ) in the pathogenesis of @entity9 ( @entity9 ). Healthy adult male C57BL/6J @entity19 were intraperitoneally injected with @entity3839 (STZ) in order to induce @entity9 . Peripheral blood @entity413 and protein, and the mRNA expression levels of C3 and @entity18544 in the spinal cord were determined. In addition, the behaviors of these @entity19 were observed. The results showed that STZ  -treated @entity19 displayed the clinical manifestations of @entity6 , and that their peripheral blood @entity413 was markedly increased. On the 21st and 28th  days following the STZ injection, the mechanical @entity158 threshold and thermal @entity158 threshold of the @entity19 were dramatically reduced (P<0.05).  Additionally, 14  days post  -STZ injection, the mRNA expression of C3 in the spinal cord was significantly increased, which continued for 28  days. On the 21st and 28th  days, the number of C3 positive cells in the spinal cord was markedly increased. Seven days after the STZ injection, the number of cells positive for @entity18544 was markedly reduced in the spinal dorsal horn and subsequently remained at a low level. The mRNA expression of @entity18544 also was significantly reduced (P<0.05) and remained so for 28  days. The reduction in the expression levels of @entity18544 occurred earlier than the changes in the expression of C3, suggesting that the downregulation of @entity18544 expression precedes, and has an important role regarding, the activation of C3 in the occurrence and development of @entity9 .

title: A preliminary study on the role of the complement regulatory protein, cluster of differentiation  55, in @entity19 with XXXX .

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity3839 :: ('MESH:D013311', 'Chemical') :: ['streptozotocin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['diabetic neuropathic pain', 'DNP']

answer: @entity9 :: (MESH:D009437,Disease) :: ['diabetic neuropathic pain']


abstract: BACKGROUND: @entity2460 ( @entity2460 ) demographic features, clinicopathologic characteristics, treatment outcome and disease-specific prognostic factors were unexplored comprehensively. METHODS: SEER program was used to identify @entity1 diagnosed with @entity2460 from 1973 to 2012. Overall collected data were analyzed by using the SPSS 18.0. RESULTS: In total, 804 cases were found including 613 cases with @entity2460 -specific mortality and 801 @entity1 were analyzed for @entity1349 ( @entity1349 ). The 3-year @entity66 ( @entity66 ), 5-year @entity66 and 10-year @entity66 were 73.3%, 65.7% and 53.3%. The 3-year @entity1349 , 5-year @entity1349 and 10-year @entity1349 were 71.9%, 63.3% and 47.3%. In the multivariate survival analysis, the age > 51 years (hazard ratio [HR] = 1.851 for @entity66 , P = 0.024 and HR = 1.652 for @entity1349 , P = 0.033; Reference [Ref]  <= 51 years for @entity66 and  <= 53 years for @entity1349 ), SEER stage metastasized @entity5 (HR = 4.269 for @entity66 , P = 0.000 and HR = 2.905 for @entity1349 , P = 0.028, Ref - localized + regional @entity5 ), pathologic grade III + IV (HR = 2.734 for @entity66 , P = 0.001 and HR = 2.585 for @entity1349 , P = 0.000, Ref - grade I + II) were adversely associated with @entity66 and @entity1349 . In addition, surgery was favorably associated with @entity66 (HR = 0.217, P = 0.045, Ref - surgery + radiotherapy). CONCLUSIONS: The surgery was an independent prognostic factor for @entity66 . The @entity1 's age, SEER stage and pathologic grade were @entity2460 -specific independent prognostic indicators for @entity66 and @entity1349 .

title: The demographic features, clinicopathologic characteristics, treatment outcome and disease-specific prognostic factors of solitary XXXX : a population-based analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['disease free survival', 'DFS']

entities_list: @entity2460 :: ('MESH:D054364', 'Disease') :: ['SFT', "Solitary fibrous tumor's"]

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['fibrous tumor']


abstract: OBJECTIVE: To explore the association between body mass index (BMI) and male @entity11810 ( @entity170 ) in a Chinese Han population. METHODS: The association of BMI with @entity170 was assessed in 276 Chinese healthy aged males for physical examination. They were classified into @entity170 , @entity2331 and normal groups according to the World Health Organization (WHO) criteria, i.e. @entity170 was defined arbitrarily when any T-score was -2.5 standard deviations or less at femoral neck, total hip or lumbar spine ( @entity1719 ) site. We also classified the subjects as different BMI groups of low weight, normal weight, @entity2973 and @entity28 . The prevalence of @entity170 was compared among different BMI groups. We determined the sensitivity, specificity and area under the curve of receiver operating characteristic (ROC) for validating the valuation of BMI to predict male primary @entity170 . RESULTS: Among them, 6/12 had @entity170 in the low weight group, 17.36% (21/121) in the normal group and 12.59% (18/143) in the @entity2973 and @entity28 group. And the difference was significant. The analysis of ROC curve showed that BMI was of limited value in predicting @entity170 (P > 0.05). CONCLUSION: BMI has a positive correlation with male @entity170 . The value of BMI is limited for predicting @entity170 in males. And the relevant factors associated with male @entity170 should to be further studied.

title: [Association of body mass index and male XXXX ].

entities_list: @entity11810 :: ('MESH:C537700', 'Disease') :: ['primary osteoporosis']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity2973 :: ('MESH:D050177', 'Disease') :: ['overweight']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia']

answer: @entity11810 :: (MESH:C537700,Disease) :: ['primary osteoporosis']


abstract: Here we examined the addition of intensity-modulated @entity236 ( @entity236 ) delivered using a linear accelerator to a myeloablative chemotherapy conditioning regimen before allogeneic hematopoietic stem cell transplantation (HSCT). In this phase I study, we enrolled 14 @entity1 with high-risk @entity1583 who received escalating doses of @entity236 at 3  Gy (n  =  3), 6  Gy (n  =  3), 9  Gy (n  =  6), and 12  Gy (n  =  2) in combination with intravenous (i.v.) @entity3118 160  mg/m(2) and targeted @entity1863 (area under the curve, 4800   M*minute). Peripheral blood mobilized stem cells were obtained from HLA-matched related (n  =  9) or unrelated (n  =  4) or 1 antigen-mismatched unrelated (n  =  1) donors. All @entity1 rapidly engrafted and recovered their immune cells. Overall, Bearman extrahematologic @entity137 were limited to grades 1 or 2, with @entity3136 grade 1 in 64% and grade 2 in 36% of the @entity1 . With a median follow-up of 1126  days (range, 362 to 1469) for living @entity1 , the overall survival was 50% and relapse-free survival was 43%. Of 7 deaths, 3 were due to relapse and 4 to transplantation-related complications. We conclude that 9  Gy @entity236 can be combined with myeloablative chemotherapy in the design of new preparative regimens for HSCT. This study was registered at clinicaltrials.gov as NCT00988013.

title: Combination of Linear Accelerator-Based Intensity-Modulated Total Marrow Irradiation and Myeloablative XXXX / @entity1863 : A Phase I Study.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancies']

entities_list: @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['total marrow irradiation', 'TMI']

answer: @entity3118 :: (MESH:C024352,Chemical) :: ['Fludarabine']


abstract: UNASSIGNED: 102 Background: After a diagnosis of @entity0 , it can be difficult for @entity1 to understand the role their primary care physician (PCP) should play in their follow up care. METHODS: 65 @entity1 (mean age 60 years, SD = 10) with @entity0 (stage 0-III) were seen by a nurse practitioner for a 60-90 minute consultative survivorship visit and received a treatment summary and personalized survivorship care plan (SCP) utilizing Carevive Care Planning Systems software. The Carevive system incorporates @entity1 -reported and clinical data to create tailored care plans with personalized recommendations for follow up care and supportive referrals, including direction to follow up with primary care for specific care and health maintenance activities. Approximately 6 weeks following their survivorship care visit, @entity1 completed a survey assessing their use of and satisfaction with the SCP. @entity1 were advised that the SCP would be mailed to their referring oncologist and primary care physician. RESULTS: Out of 65 sent, 35 surveys have been completed to date. Survivors were diagnosed approximately 10 months prior, and all were within 6 months following completion of treatment. All @entity1 (100%) reported that they read, or planned to read, their survivorship care plan packet carefully. While all care plans included a recommendation to follow up with their PCP, only (71%) of survivors remembered receiving this recommendation. Of those who did, most (74%) had either seen or scheduled an appointment with their PCP. @entity1 who reported higher @entity148 at the time of the survivorship visit were more likely to report that the follow up care plan helped them take action about seeing their PCP (p = .03). CONCLUSIONS: Coordination between primary and oncology care providers has previously been shown to improve the quality of care for @entity5 survivors. SCPs that emphasize the importance of and activities to be undertaken in primary care may help to improve this coordination. Continuation of this research will help to better understand how to integrate the primary care physician into @entity5 follow up care. Updated data will be shared at time of presentation.

title: Integrating the primary care physician into XXXX follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: The aim of this study was to assess protein overexpression and gene copy number alterations of MET in @entity43 , and to assess its potential as a novel therapeutic target. Ninety cases of clear-cell @entity420 were analyzed for MET protein overexpression and copy number alterations of the MET gene by immunohistochemistry and brightfield double in situ hybridization, respectively. In addition, 101 cases of the @entity43 at advanced stages were also evaluated for comparison. MET overexpression was assigned when complete membrane staining with moderate or strong intensity was observed in at least 10% of the @entity5 cells examined. Double in situ hybridization was determined as positive when the @entity5 exhibited high-level polysomy (>= 4 copies in >= 40% of @entity5 cells) or @entity74 . MET overexpression was detected in 20 of 90 clear-cell @entity420 (22%) and none of 111 @entity43 . Double in situ hybridization was positive in 21 of 89 informative clear-cell @entity420 (24%) and only 3 @entity43 (3%). In the whole population, true amplification of the MET gene was detected only in the clear-cell @entity420 histology (five cases, 6%). In clear-cell @entity420 , double in situ hybridization positivity was highly correlated with the presence of MET overexpression and a poorly differentiated histology of @entity5 (P=0.0105 and 0.00038, respectively). For the @entity1 with clear-cell @entity420 , MET overexpression, as well as advanced clinical stage and the poorly differentiated histology of @entity5 , was identified as an independent unfavorable prognostic factor for overall survival. In conclusion, among @entity43 , the amplification of the MET proto-oncogene is highly selective and commonly occurs in clear-cell @entity420 . MET could serve as a biomarker for the prognostication of @entity1 with clear-cell @entity420 and @entity5 progression, and has potential as a novel therapeutic target for this @entity189 .

title: Gene amplification and protein overexpression of MET are common events in XXXX : their roles in @entity5 progression and prognostication of the @entity1 .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinomas', 'ovarian clear-cell adenocarcinoma', 'non-clear-cell type ovarian carcinomas']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['MET gene amplification']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian clear-cell adenocarcinoma']


abstract: OBJECTIVE: To evaluate the efficacy of a programme of group education for @entity6 , which succeeded in reducing base glucaemia, body mass index and glycosylated haemoglobin, stimulating insulin-treated @entity1 ' self-monitoring of glucaemia, improving their understanding of the disease, and bringing into group education 75% of the target population. DESIGN: A controlled clinical trial with paired samples, lasting two years. SETTING: "Las Fuentes Norte" Health Centre, Zaragoza. @entity1 : 243 type-2 @entity6 , distributed at random, with 120 in the intervention group and 123 in the control group. All @entity1 with no history of group education in the previous two years and with no restrictions on their attending talks and monitoring were included. No-one gave up in the first year; 9 did in the second year. INTERVENTION: Group health education workshop for two days in the first and second years. MEASUREMENTS AND MAIN RESULTS: In the intervention group, at the end of the study, success in the survey increased by 4.2; base glucaemia dropped by 17.1 mg/dl, glycate haemoglobin went down by 0.5, and self-analysis went up by 14.2%, all with significant differences (p < 0.005 and CI 95%). The body mass index went down by 0.3 without significant differences. Knowledge was lost between the first and second year, with worse metabolic control. In the control group there were no significant differences in any variable. CONCLUSIONS: A stable programme of group education may be effective, especially because of the increase in knowledge of the disease, fostering excellent conditions for a change to a healthier life-style.

title: [The education of type-2 XXXX : why not in groups?].

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetics']


abstract: Surgical resection is thought to be the best treatment for @entity96 , including @entity157 and metastatic @entity96 if there are a small number of @entity5 . @entity96 is one of the main causes of @entity204 from @entity5 worldwide. The prognosis of @entity96 is still poor. Mutation of @entity10740 , which is well known as a @entity5 suppressor gene, is observed in many cases of advanced @entity96 . @entity5 gene therapy using @entity10740 , which transduces the wild-type @entity10740 gene in the @entity5 , is a promising new strategy for treating @entity96 . Selective and less invasive gene delivery to the @entity96 is necessary for clinical @entity96 gene therapy. The first purpose of the current study was to determine the best way to deliver the gene of interest to the @entity96 selectively. The second purpose was to study the @entity5 suppressive effect of intrahepatic arterial injection of an adenovirus vector with the @entity10740 gene (AdCMV- @entity10740 ), followed by administration of CDDP and noting its side effects. We injected AdCMV-LacZ via hepatic arteries of @entity35 bearing RCN-9 colon @entity5 @entity3 in the liver. Injection via the hepatic artery resulted in more successful gene transduction to the @entity96 in a @entity5 -selective manner than did injection via the portal vein. At 48 hrs after arterial injection of AdCMV- @entity10740 , CDDP (3 mg/kg) was administered in the peritoneal cavity of each @entity35 . The use of CDDP with arterial injection of AdCMV- @entity10740 resulted in more extensive apoptosis in the @entity35 @entity96 without any deterioration in liver function. In conclusion, hepatic arterial injection of an adenovirus vector is better than portal vein injection for gene transduction efficiency, and causes no liver function disorder even when the injection is combined with CDDP.

title: Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV- XXXX combined with CDDP to @entity35 liver @entity3 .

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumor', 'liver tumors', 'Liver carcinoma', 'liver carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']

answer: @entity10740 :: (301300(Tax:10116),Gene) :: ['p53']


abstract: OBJECTIVE: To evaluate the effects of @entity69039 on the formation of adhesions and anastomotic healing in the left colon of @entity35 . METHODS: We divided 40 @entity35 into two groups of 20 animals, administration of @entity69039 (study group-E) or saline (control group-C). Each group was divided into subgroups containing 10 animals each for euthanasia in the third (C3 and E3) or the seventh (E7 and C7) postoperative days. The @entity35 were submitted to section of the left colon and end-to-end @entity254 . On the day of reoperation, we evaluated the total amount of adhesions and removed a colonic segment containing the @entity254 for histopathological analysis, assessment of rupture strength and @entity720 concentration. RESULTS: There was no difference between groups in relation to clinical outcome. Two animals in the study group had blocked anastomotic leakage. The animals that received @entity69039 had the number of intracavitary adhesions and adhesions to the @entity254 similar to the control group. The anastomoses from the group E3 animals showed lower resistance to rupture the one from the C3 group (p = 0.04). This effect did not occur on the seventh postoperative day (p = 0.37). There was no significant difference between groups in relation to histopathology and @entity720 concentration in the anastomoses. CONCLUSION: The use of @entity69039 was associated with decreased tensile strength of left colon @entity254 in @entity35 in the third postoperative day.

title: Effects of XXXX on the healing of left colon anastomoses of @entity35 .

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline']

entities_list: @entity69039 :: ('MESH:C013855', 'Chemical') :: ['bromopride']

answer: @entity69039 :: (MESH:C013855,Chemical) :: ['bromopride']


abstract: BACKGROUND: The objective was to evaluate the diagnostic accuracy of ultrasmall superparamagnetic @entity1933 (USPIO)-enhanced magnetic resonance imaging (MRI) compared to plain MRI in @entity1 with a clinical N+ neck using histology as a gold standard. MATERIALS AND METHODS: Twenty-eight @entity1 underwent unenhanced and USPIO-enhanced MRI using T1-weighted spin echo (SE) sequences and high resolution Turbo-Spin-Echo (TSE) T2-weighted sequences, as well as T2-weighted Gradient Echo (GE) sequences in axial and sagittal slice orientation. The signal intensity (SI) decrease was measured by a region of interest evaluation and visual analysis was performed. RESULTS: Histopathological evaluation of 363 lymph nodes revealed 34 as metastatic. USPIO MRI detected 28 @entity3 (sensitivity 82.3%) and 329 non-metastatic lymph nodes (specificity 100%). Regarding lymph node size, USPIO MRI was correct in all @entity1 who underwent surgery. One lymph node with microinfiltration of @entity5 cells was detected by USPIO MRI. CONCLUSION: There were no side-effects during or after application of the contrast agent. This study confirms the efficacy of MRI with USPIO in @entity1 with @entity135 . USPIO-enhanced MRI could have an important effect on surgery planning. Because of its high specificity, USPIO-enhanced MRI seems to be a diagnostic modality able to differentiate borderline-sized lymph nodes.

title: The efficacy of MRI with ultrasmall superparamagnetic XXXX particles (USPIO) in @entity135 .

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity1933 :: ('MESH:C000499', 'Chemical') :: ['iron oxide']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity1933 :: (MESH:C000499,Chemical) :: ['iron oxide']


abstract: @entity2842 ( @entity2842 ) is a chemokine involved in the macrophage infiltration of @entity5 tissue. Tumor associated macrophages (TAMs) are a population of mononuclear-phagocytic cells, which can express complex functions related to @entity5 biology. The present study was designed to analyse the expression of @entity2842 in parenchymal and stromal elements on frozen sections of 27 @entity9962 not otherwise specified (NOS) by immunohistochemistry. The expression of @entity2842 in @entity5 parenchyma and the degree of @entity5 differentiation were assessed. @entity2842 was detected in the @entity513 . Positive immunoreactivity manifested as diffuse, homogeneous, moderate or strong, cytoplasmic staining, confined to @entity5 epithelium. Generally, @entity2842 -negative @entity5 tended to be well differentiated, while chemokine-positive @entity5 exhibited a low level of differentiation. @entity2842 immunoreactivity was also present in TAMs ( @entity469 positive cells) in 23 of 27 @entity5 , and in endothelial cells in 11 of 27 @entity5 . These results indicate that parenchymal and, more variably, stromal elements of @entity1 invasive @entity513 NOS can express @entity2842 in vivo. Additionally, these findings suggest that @entity2842 expression in @entity5 parenchyma is correlated with the histological grade of @entity9962 .

title: Expression of @entity2842 in XXXX invasive ductal breast cancer.

entities_list: @entity9962 :: ('MESH:D018270', 'Disease') :: ['ductal invasive breast carcinoma', 'breast invasive ductal carcinomas']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['parenchyma in 15 of 27 ductal carcinomas', 'ductal carcinomas']

entities_list: @entity2842 :: ('6347', 'Gene') :: ['Monocyte chemotactic protein-1', 'MCP-1']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: PURPOSE: The oligometastatic state is an intermediate state between a malignancy that can be completely eradicated with conventional modalities and one in which a palliative approach is undertaken. Clinically, high rates of @entity5 control are possible with stereotactic ablative radiation therapy (SABR), using precisely targeted, high-dose, low-fraction radiation therapy. However, in @entity320 , virtually all @entity1 develop progression systemically at sites not initially treated with ablative radiation therapy that cannot be managed with conventional chemotherapy and immunotherapy. We have demonstrated in @entity19 that intravenous administration of @entity8310 virus (VSV) expressing defined @entity5 -associated antigens (TAAs) generates systemic immune responses capable of clearing established @entity5 . Therefore, in the  present preclinical study, we tested whether the combination of systemic VSV-mediated antigen delivery and SABR would be effective against @entity66 . METHODS AND MATERIALS: We generated a model of @entity320 in C57BL/6 immunocompetent @entity19 and then used a combination of SABR and systemically administered VSV- @entity2796 viral immunotherapy to treat both @entity262 . RESULTS: Our data showed that SABR generates excellent control or cure of local, clinically detectable, and accessible @entity5 through direct cell ablation. Also, the immunotherapeutic activity of systemically administered VSV- @entity2796 generated T-cell responses that cleared subclinical @entity3 . We also showed that SABR induced weak T-cell-mediated @entity5 responses, which, particularly if boosted by VSV- @entity2796 , might contribute to control of @entity262 . In addition, VSV- @entity2796 therapy alone had significant effects on control of both local and @entity3 . CONCLUSIONS: We have shown in the present preliminary @entity19 study using a single @entity5 model that this approach represents an effective, complementary combination therapy model that addresses the need for both systemic and local control in @entity320 .

title: Definitive Management of XXXX in a @entity19 Model Using Combined  Ablative Radiation Therapy and  Viral  Immunotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['oligometastatic disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'local tumor', 'tumors']

entities_list: @entity8310 :: ('MESH:D054243', 'Disease') :: ['vesicular stomatitis']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['local and systemic disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['oligometastatic melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['Oligometastatic Melanoma']


abstract: To examine the role of protein kinase A (EC 2.7.1.37) isozymes in the @entity1968 -induced growth inhibition and neuronal differentiation, we investigated the changes of protein kinase A isozyme patterns in @entity1968 -treated SH-SY5Y @entity1 @entity521 cells. @entity1968 induced growth inhibition and neuronal differentiation of SH-SY5Y cells in a dose- and time-dependent manner. Neuronal differentiation was evidenced by extensive neurite outgrowth, decrease of @entity4180 oncoprotein, and increase of @entity13573 mRNA. Type II protein kinase A activity increased by 1.5-fold in differentiated SH-SY5Y cells by @entity1968 treatment. The increase of type II protein kinase A was due to the increase of @entity37500 have been known to play important role(s) in the growth inhibition and differentiation of @entity5 cells, we further investigated the role of the increased type II protein kinase A by overexpressing @entity37500 in SH-SY5Y cells. The growth of @entity37500 -overexpressing cells was slower than that of parental cells, being comparable to that of @entity1968 -treated cells. @entity1968 treatment further increased the @entity37500 level and further inhibited the growth of @entity37500 -overexpressing cells, showing strong correlation between the level of @entity37500 and growth inhibition. However, @entity37500 -overexpressing cells did not show any sign of neuronal differentiation and responded to @entity1968 in the same way as parental cells. These data suggest that protein kinase A participates in the @entity1968 -induced growth inhibition through the up-regulation of @entity37500 /type II protein kinase A.

title: Participation of type II protein kinase A in the @entity1968 -induced growth inhibition of SH-SY5Y @entity1 XXXX cells.

entities_list: @entity37500 :: ('5577', 'Gene') :: ['RIIbeta', 'RIIbeta and Calpha subunits. Since type II protein kinase A and RIIbeta']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma']

entities_list: @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid', 'Retinoic acid']

answer: @entity521 :: (MESH:D009447,Disease) :: ['neuroblastoma']


abstract: BACKGROUND: To evaluate hospital costs and reimbursement for open (OAAA) and endovascular (EVAAA) repair of @entity1028 . STUDY DESIGN: Review of all @entity1 who underwent OAAA or EVAAA in two teaching hospitals during the period January 1, 2000, to December 31, 2000, was completed for the following: demographics, Diagnosis Related Group (DRG), resource use, length of stay, hospital costs, and reimbursement data. RESULTS: There were 130 @entity1028 performed. Fifty-seven (44%) OAAA were completed; EVAAA was attempted in 73 (56%). Seventy EVAAA @entity1 (96%) had endografts placed, and three (4%) required conversion to open repair. Significant differences were noted between OAAA and EVAAA in operative time (311.7 +/- 107.5 minutes versus 263.4 +/- 110.8 minutes, respectively, p = 0.02), ICU admission and length of stay (100%, 5.0 +/- 6.1 days versus 29%, 1.4 +/- 7.1 days, respectively, p = 0.003), and hospital length of stay (12.6 +/- 14.8 days versus 4.9 +/- 13.4 days, respectively, p = 0.002). Total costs were  17,539.00 for EVAAA and  9,042.00 for OAAA. EVAAA was profitable ( 3,072.00) for Medicare DRG 110 classification, but significant loss occurred with DRG 111 ( 5,065.00). Contract renegotiation with private payers (to cover graft costs) was necessary to avoid substantial per- @entity1 loss ( 12,108.00). Overall net per- @entity1 profit for EVAAA was  737.00. CONCLUSIONS: @entity1028 repair is significantly more expensive than open repair, with the major portion attributed to graft cost. Although ICU use and total length of stay decreased with EVAAA, overall costs were not substantially reduced. Hospitals must develop new financial strategies and improve the efficiency of their infrastructures in order to offer EVAAA.

title: Hospital costs for endovascular and open repair of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['Endovascular abdominal aortic aneurysm', 'abdominal aortic aneurysm', 'abdominal aortic aneurysm procedures']

answer: @entity1028 :: (MESH:D017544,Disease) :: ['abdominal aortic aneurysm']


abstract: UNASSIGNED: @entity4810 is a complex multifactorial and polygenic disease, and genetic factors play an important role in its formation and development. Recently, the association between @entity23385 ( @entity23385 ) gene polymorphisms and @entity4810 risk has attracted widespread attention due to the unique biological functions of FSH. The aim of this study was to further explore the associations between the @entity67178 and @entity23384 polymorphisms of the @entity23385 gene and @entity4810 . A case-control study of 212 @entity249 and 164 fertile @entity1 from North China was performed. @entity23385 polymorphism genotypes were obtained through direct DNA sequencing. A meta-analysis was also performed. In the single-site association analysis, no significant associations were identified between @entity23385 @entity67178 and @entity23384 polymorphisms and @entity4810 (P > 0.05). However, we found that the combined genotypic frequency of Thr/Ala + @entity2734 / @entity2734 was higher in @entity249 @entity1 than in controls (6.6 vs 1.8%; odds ratio (OR) = 3.795; 95% confidence interval (CI): 1.072-13.434, P = 0.027). In the meta-analysis, there was also no evidence of @entity23385 polymorphism ( @entity66575 and @entity70411 ) association with @entity4810 (P > 0.05). However, we found that the combined genotypes Thr/Thr + @entity2734 / @entity2734 had an increased risk of @entity4810 (OR = 1.238; 95%CI: 1.001-1.537, P = 0.049). Our studies further confirmed reports that there were no significant associations between the @entity23385 @entity67178 and @entity23384 polymorphisms and @entity4810 risk. However, a combined @entity23385 genotype showed significant association with @entity4810 .

title: @entity23385 gene @entity67178 and @entity23384 polymorphisms in @entity249 XXXX : an association study in North China and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'patients']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertile']

entities_list: @entity4810 :: ('MESH:D007248', 'Disease') :: ['Male infertility', 'male infertility']

entities_list: @entity23385 :: ('2492', 'Gene') :: ['FSHR', 'follicle stimulating hormone receptor']

entities_list: @entity67178 :: ('p|SUB|T|307|A', 'ProteinMutation') :: ['Thr307Ala']

entities_list: @entity23384 :: ('p|SUB|N|680|S', 'ProteinMutation') :: ['Asn680Ser']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: OBJECTIVE: To investigate @entity892 (binocular single vision [ @entity27654 ] test) and @entity1319 (uniocular field of fixation [UFOF] test) characteristics in @entity8924 of the orbit and their value in @entity174 management. MATERIAL AND METHODS: @entity1 with isolated @entity8924 treated from 2000 to 2010 were included. @entity27654 scores were stratified into three categories: low @entity27654 category (0-60); moderate @entity27654 category (61-80), and high @entity27654 category (81-100). UFOF scores were also divided into three categories: low score (60-240), moderate score (241-270), and high score (271-365) categories. RESULTS: A total of 183 @entity1 (106 surgically and 77 conservatively managed) met the inclusion criteria. There was no significant improvement in @entity27654 postoperatively in surgically managed @entity1 with preoperatively high @entity27654 , whereas there was significant improvement (p  <  0.05) for the high @entity27654 category in the conservative group. Preoperative @entity27654 was found to be significantly related (p  <  0.05) to postoperative @entity27654 , subjective @entity892 outcome, follow-up time, and number of follow-up visits. However, improvement of @entity27654 score in the surgical group was not found to be significantly correlated with subjective outcome in relation to @entity892 . Preoperative UFOF score has no influence on subjective outcome in relation to @entity892 . Surgical timing, approach, and choice of implant material were not found to be statistically related to final @entity892 outcome, follow-up time, or number of follow-up visits. CONCLUSIONS: @entity27654 is better correlated with @entity892 outcome, follow-up time, and number of follow-up visits than is UFOF. On the basis of this study, surgical intervention would not be recommended for blow-out @entity174 cases with @entity27654 score >80% for correction of @entity892 alone.

title: @entity892 and XXXX in orbital @entity8924 : 10-year retrospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity8924 :: ('MESH:D009917', 'Disease') :: ['blow-out fractures']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['ocular motility']

answer: @entity1319 :: (MESH:D015835,Disease) :: ['ocular motility']


abstract: BACKGROUND: The leaf is an important plant organ, and how it will respond to future global warming is a question that remains unanswered. The effects of experimental warming on leaf photosynthesis and respiration acclimation has been well studied so far, but relatively little information exists on the structural and biochemical responses to warming. However, such information is very important to better understand the plant responses to global warming. Therefore, we grew @entity958 at the three day/night temperatures of 23/18  C (ambient temperature), 25.5/20.5  C (elevated by 2.5  C) and 28/23  C (elevated by 5  C) to simulate the middle and the upper projected warming expected within the 21st century for this purpose. RESULTS: The 28/23  C treatment significantly reduced the life span, total biomass and total weight of seeds compared with the other two temperatures. Among the three temperature regimes, the concentrations of starch, @entity38 , and @entity1521 were the lowest at 28/23  C, whereas the total weight of seeds, concentrations of @entity38 and @entity1521 , stomatal density (SD), stomatal conductance (gs), net @entity515 assimilation rate (A) and transpiration rate (E) were the highest at 25.5/20.5  C. Furthermore, the number of chloroplasts per cell and mitochondrial size were highest at 25.5/20.5  C and lowest at 28/23  C. CONCLUSIONS: The conditions whereby the temperature was increased by 2.5  C were advantageous for @entity958 . However, a rise of 5  C produced negative effects, suggesting that lower levels of warming may benefit plants, especially those which belong to the same functional group as @entity958 , whereas higher levels of warming may produce negative affects. In addition, the increase in A under moderately warm conditions may be attributed to the increase in SD, @entity38 content, and number of chloroplasts. Furthermore, starch accumulation in chloroplasts may be the main factor influencing chloroplast ultrastructure, and elevated temperature regulates plant respiration by probably affecting mitochondrial size. Finally, high SOD and CAT activities may enable plants grown at elevated temperatures to exhibit relatively high tolerance to temperature stress, thus alleviating the harmful effects of @entity224 anion radicals and @entity273 .

title: The effect of experimental warming on leaf functional traits, leaf structure and leaf biochemistry in XXXX .

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis thaliana', 'Arabidopsis']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity1521 :: ('CHEBI:26271', 'Chemical') :: ['proline']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

entities_list: @entity38 :: ('MESH:D002734', 'Chemical') :: ['chlorophyll']

answer: @entity958 :: (3702,Species) :: ['Arabidopsis thaliana']


abstract: The effect of glucagon on renal haemodynamics in @entity742 is controversial. In this study we have examined the effects of perfused glucagon on renal blood flow (RBF) in six conscious @entity742 bilaterally implanted with transit-time ultrasonic flow metering probes around the renal arteries. Glucagon was perfused intravenously over 90 min at doses of 3.12, 6.25, 12.5, 25, 50 and 100 ng kg(-1) min(-1). Mean RBF was calculated over 10 min periods. Blood samples were taken to monitor the time course of the changes in glycaemia and glucagonaemia. The perfusions of glucagon induced rapid and progressive dose-dependent increases in RBF (9-19.2 %, P < 0.05) and glycaemia (29-155 %, P < 0.05) for doses of 25-100 ng kg(-1) min(-1). High positive correlations were found between the increases in RBF and glucagonaemia (R2 = 0.95) and between the increases in RBF and glycaemia (R2 = 0.96). At the lowest doses of glucagon (3.12-12.5 ng kg(-1) min(-1)), the increase in RBF was highly significant; however, the rise in @entity413 level was not. At the highest doses (25-100 ng kg(-1) min(-1)) the time course of the changes in RBF was parallel to that of glucagonaemia throughout the perfusion time. However, between minutes 45 and 90 of the glucagon perfusion, the increase in RBF was the inverse of the change in glycaemia, which decreased. One hour after the end of the 50 and 100 ng kg(-1) min(-1) perfusions, the @entity413 levels were still significantly higher than the baseline, while the RBF values were not. These results are consistent with the idea that the enhanced RBF cannot be attributed to a rise in blood @entity413 level. They also show that the haemodynamic response to glucagon perfusion was more sensitive than the metabolic response. It is concluded that the intravenous perfusion of physiological doses of glucagon induced a highly sensitive dose-dependent increase in RBF in @entity742 .

title: Effects of intravenous perfusion of glucagon on renal blood flow in conscious XXXX .

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity742 :: (9940,Species) :: ['sheep']


abstract: AIM: To identify differences between defense styles and mechanisms in @entity13549 @entity1 with or without @entity9 and their relationship to quality of life. STUDY DESIGN: The study included 37  @entity13549 @entity1 with @entity9 (SNP), 36  @entity13549 @entity1 without @entity9 and 38  healthy subjects. @entity158 severity was measured using the Visual Analogue Scale (VAS). Psychological condition was assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Defense mechanisms were assessed using a 40-item Defense Style Questionnaire (DSQ-40) and quality of life was assessed using Short Form-36 (SF-36). RESULTS: BDI and BAI scores were significantly higher in the SNP group (p   <   0.001). Idealization and immature defense styles, as well as isolation, displacement and somatization were significantly higher in the SNP group (p   <   0.05). SF-36 parameters also differed significantly between the groups, with controls having the best scores and the SNP group the worst. In linear regression analysis, acting out and BDI were found to affect the @entity158 domain of the SF-36 (p   <   0.001). CONCLUSION: The acting out defensive style and BDI were independently associated with @entity158 -related quality of life. In the SNP group, significant differences were found in the immature and neurotic styles of the defense mechanisms.

title: @entity13549 XXXX with @entity9 and its relationship to quality of life.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Magnetic activated @entity505 composite ( @entity68518 /AC, MACC) was prepared by a co-precipitation-calcination method. The MACC consisted of porous micro-particle morphology with homogeneously distributed @entity68518 and possessed high magnetic saturation moment (8.1emug(-1)). The performance of MACC was evaluated as catalyst and regenerable adsorbent via @entity15909 ( @entity18809 , @entity43992 (  )) activation for @entity6693 (MB) removal. Optimum @entity68518 /AC w/w ratio was 1:1.5 giving excellent performance and can be reused for at least 3 cycles. The presence of common inorganic ions, namely Cl(-) and @entity8326 did not exert significant influence on MB degradation but humic acid decreased the MB degradation rate. As a regenerable adsorbent, negligible difference in regeneration efficiency was observed when a higher @entity43992 (  ) dosage was employed but a better efficiency was obtained at a lower MACC loading. The factors hindering complete MACC regeneration are MB adsorption irreversibility and AC surface modification by @entity18809 making it less favorable for subsequent MB adsorption. With an additional mild heat treatment (150  C) after regeneration, 82% of the active sites were successfully regenerated. A kinetic model incorporating simultaneous first-order desorption, second-order adsorption and pseudo-first order degradation processes was numerically-solved to describe the rate of regeneration. The regeneration rate increased linearly with increasing @entity43992 (  ):MACC ratio. The MACC could potentially serve as a catalyst for @entity18809 activation and regenerable adsorbent.

title: Performance of magnetic activated @entity505 composite as XXXX activator and regenerable adsorbent via sulfate radical-mediated oxidation processes.

entities_list: @entity6693 :: ('MESH:D008751', 'Chemical') :: ['methylene blue']

entities_list: @entity15909 :: ('MESH:C038288', 'Chemical') :: ['peroxymonosulfate']

answer: @entity15909 :: (MESH:C038288,Chemical) :: ['peroxymonosulfate']


abstract: PURPOSE: @entity1619 ( @entity1619 ) is usually @entity2902 (+) and rapidly fatal. Anti- @entity2902 recombinant immunotoxin LMB-2 had phase I activity limited by immunogenicity and rapid growth. To prevent antidrug antibodies and @entity1778 progression between cycles, a phase II trial was performed with LMB-2 after @entity786 and @entity3118 . EXPERIMENTAL DESIGN: @entity1619 @entity1 received @entity786 and @entity3118 days 1 to 3 and 2 weeks later began up to 6 cycles at 3-week intervals of @entity786 and @entity3118 days 1 to 3 followed by LMB-2 30-40  g/kg i.v. days 3, 5, and 7. Three different dose levels of @entity786 and @entity3118 were used, 20+200 (n = 3), 25+250 (n = 12), and 30+300 mg/m(2) (n = 2). RESULTS: Of 17 @entity1 enrolled and treated with @entity3118 and @entity786 for cycle-1, 15 received subsequent cycle(s) containing LMB-2 and were therefore evaluable for response. Lack of antibody formation permitted retreatment in most @entity1 . Of 10 evaluable @entity1778 @entity1 receiving 25+250 or 30+300 mg/m(2) of @entity3118 and @entity786 , 6 (60%) achieved @entity10911 (20%) partial remission (PR), and all 5 with >25% @entity1778 cells achieved CR. No responses were achieved in 5 with @entity1619 or lower @entity3118 and @entity786 doses. Median CR duration for the 6 CRs was 40 weeks. One is without detectable @entity1619 at 47 months. @entity137 was mostly attributable to @entity3118 and @entity786 . Capillary leak from LMB-2 was non-dose limiting. One @entity1 in CR died of a preexisting @entity281 . CONCLUSIONS: LMB-2, administered with @entity3118 and @entity786 to prevent antidrug antibodies and rapid intercycle progression, is highly effective in achieving CR in @entity1778 @entity1619 . @entity3118 and @entity786 dose/schedule is important for safety and efficacy in this high-risk population. Clin Cancer Res; 22(2); 310-8.   2015 AACR.

title: Complete Remissions of @entity1619 with Anti- XXXX Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity10911 :: ('1380', 'Gene') :: ['complete remission (CR) and 2']

entities_list: @entity1619 :: ('MESH:D015458', 'Disease') :: ['Adult T-cell leukemia', 'lymphomatous ATL', 'ATL']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine', 'fludarabine']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia', 'leukemic']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity2902 :: (3559,Gene) :: ['CD25']


abstract: BACKGROUND: Previous studies have demonstrated that @entity1 with @entity1569 have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of @entity5144 , there have been few large-scale observational studies focused on this condition. OBJECTIVE: To assess rates of cardiovascular, autoimmune, @entity166 and other conditions in @entity1 with @entity1569 or @entity5144 ( @entity5144 ). METHODS: The data for this retrospective study were obtained from the Clinical Practice Research Datalink (CRPD). Cohorts of @entity1 with @entity1569 (n  =  27  672; mild, n  =  22  174, severe, n  =  5498) and @entity5144 (n  =  1952) were generated based on the diagnosis made by general practitioner or specialist recorded in CPRD between 2006 and 2010. Frequencies of comorbidities at baseline and incidence rate ratios (IRR) of medical conditions occurring during follow-up were calculated and compared between groups. Cox proportional hazard models were employed to compare hazard ratios (HR) of comorbidities across the same subpopulations previously described. RESULTS: Significant differences in the unadjusted risk of @entity65 , hyperlipidaemia, @entity6 , @entity1489 and @entity792 were observed between @entity1 with differing severity of @entity1569 or between @entity5144 and @entity1569 @entity1 . The adjusted HR analyses confirmed @entity1 with severe @entity1569 had significantly higher rates of several conditions including @entity6 (1.23; 95% CI: 1.01-1.51) and @entity309 (2.88; 95% CI: 2.25-3.67) compared to @entity1 with mild @entity1569 . @entity1 with @entity5144 had significantly higher adjusted rates of @entity101 (1.30; 95% CI: 1.01-1.68), @entity309 (6.93; 95% CI: 5.45-8.80) and @entity1691 (6.98; 95% CI: 2.37-20.58) compared to those with severe @entity1569 . CONCLUSION: @entity1 with mild @entity1569 are less affected by comorbid conditions than those with severe @entity1569 , and @entity1 with @entity1569 are less affected by comorbidities than those with @entity5144 . Given the differences observed across severities of @entity1569 and between @entity1569 and @entity5144 , each @entity1 subgroup should be taken into consideration in clinical practice and future research.

title: Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in @entity1 with XXXX : a retrospective study using Clinical Practice Research Datalink.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin cancer']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['PSA', 'psoriatic disease', 'psoriatic arthritis']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity5144 :: (MESH:D015535,Disease) :: ['psoriatic or psoriatic arthritis']


abstract: OBJECTIVES: This study sought to evaluate the incidence of @entity397 ( @entity397 ), @entity2681 ( @entity2681 ), and calcified nodule (CN) using optical coherence tomography (OCT) in @entity1 with @entity583 ( @entity583 ); to compare detailed morphologic plaque characteristics of @entity397 , @entity2681 , and CN with optical coherence tomography and intravascular ultrasound; and to compare the post-procedure outcomes among @entity397 , @entity2681 , and CN. BACKGROUND: The incidence and detailed morphologic characteristics of @entity397 , @entity2681 , and CN in @entity583 @entity1 and their outcome after percutaneous coronary intervention (PCI) are unknown. METHODS: A total of 112 @entity583 @entity1 who underwent PCI within 12 h from symptom onset were included. Both optical coherence tomography and intravascular ultrasound were performed following aspiration thrombectomy. RESULTS: The incidence of @entity397 , @entity2681 , and CN was 64.3%, 26.8%, and 8.0%, respectively. @entity2681 and CN, compared with @entity397 , had more @entity82 (p  < 0.001 and p  < 0.001) and less thin-cap @entity1856 (p  < 0.001 and p  < 0.001) as well as smaller plaque burden (p  = 0.003 and p  = 0.001) and remodeling index (p  = 0.003 and p  < 0.001). @entity2681 had greater plaque eccentricity index than @entity397 and CN (p  < 0.001 and p  < 0.001). CN had greater calcified arc and shallower @entity460 than @entity397 (p  < 0.001 and p  < 0.001) or @entity2681 (p  < 0.001 and p  < 0.001). More than one-half of CN had negative remodeling. @entity2681 had a lower incidence of no-reflow phenomenon after PCI than @entity397 (p  = 0.011). CONCLUSIONS: @entity2681 was the underlying mechanism in one-fourth of @entity583 . @entity2681 was characterized by @entity82 . CN was characterized by superficial large @entity460 and negative remodeling. @entity2681 was associated with less @entity16 after PCI.

title: A Combined Optical Coherence Tomography and Intravascular Ultrasound  Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in  XXXX With ST-Segment Elevation @entity583 : Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous plaque', 'eccentric fibrous plaque']

entities_list: @entity2681 :: ('MESH:D014077', 'Disease') :: ['PE', 'plaque erosion']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['microvascular damage']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['plaque rupture', 'PR']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1856 :: ('MESH:D058226', 'Disease') :: ['fibroatheroma']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: PURPOSE: @entity145 are sometimes encountered in MRIs performed for a variety of reasons. In @entity1 with @entity302 , particularly those with @entity302 , @entity145 are often assumed to be related to their @entity410 focus. We conducted a study to investigate this putative relationship. METHODS: A retrospective study on the incidence of @entity145 was performed in @entity1 seen in our @entity302 Clinic who had CT or MRI scans, interictal EEGs or ictal EEGS. Locations of @entity410 foci in these @entity1 were defined from clinical and electrophysiologic data. RESULTS: Seventeen of 867 @entity1 had @entity145 . Twelve @entity1 had temporal lobe cysts and only 3 of them had temporal lobe @entity410 . Four @entity1 @entity75 and only 1 had @entity410 ipsilateral to the cyst. One @entity1 had a cerebello-pontine angle @entity410 . Thus, clinical manifestations of @entity410 and EEG findings (interictal and/or ictal) indicated that the @entity410 focus was adjacent to the cysts in only 4 @entity1 (23.5%). CONCLUSIONS: Our findings suggest that @entity145 are often an incidental finding in @entity1 with @entity302 and do not necessarily reflect the location of the @entity410 focus.

title: What is the relationship between @entity145 and XXXX foci?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'cyst and frontal lobe seizures', 'frontal lobe seizures']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['had frontal lobe cysts']

entities_list: @entity145 :: ('MESH:D016080', 'Disease') :: ['arachnoid cysts', 'Arachnoid cysts']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['refractory epilepsy', 'epilepsy', 'Epilepsy']

answer: @entity410 :: (MESH:D012640,Disease) :: ['seizure']


abstract: BACKGROUND: Benign tracheo-bronchial @entity5 are rare, but potentially dangerous conditions with life threatening consequences. @entity5 removal should be pursued by methods minimizing the procedural stress. The role of endoscopic treatment, as an alternative to open surgery, remains controversial. OBJECTIVES: report the twelve-years endoscopic experience in Rome, Italy. Fifty-seven benign tracheo- @entity5 were diagnosed and 130 tracheo-bronchial resections by rigid bronchoscopy performed. METHODS: we identified histotypes associated with higher recurrence rate and assessed their relationship with gender, age and tracheo-bronchial location. We provided data on safety and complications and suggested a decision making flow chart to address the @entity1 to endoscopic resection. RESULTS: complete eradication after a single procedure without recurrence at 2 years was obtained in 63.1% of cases (36/57). Need of a second intervention within few months but no further recurrence at follow up was seen in a further 8.8% (5/57). Histotypes associated with recurrence were @entity1185 and @entity1127 . Seven @entity1 (12.3%) were addressed to surgery because of multiple recurrence. Ten @entity1 (17.5%) were lost at follow up. In case of recurrence, the bronchial biopsy was always repeated and no malignant transformation was observed. No major complications, pneumothorax or @entity14303 occurred. CONCLUSIONS: endoscopic treatment of benign tracheo @entity5 is safe and effective, provided that the procedure is carefully and systematically planned. The rate of eradication is satisfactory and the incidence of complications negligible. This will encourage this approach as first line treatment especially in @entity1 , frequently elderly @entity1 , having increased surgical risk due to concomitant @entity1576 or major comorbidities.

title: Endoscopic treatment of primary XXXX : Results from a large consecutive case series and decision making flow chart to address bronchoscopic excision.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity1127 :: ('MESH:D011127', 'Disease') :: ['inflammatory polyp']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['bronchial tumors', 'Tumor', 'neoplasms']

entities_list: @entity1185 :: ('MESH:D010212', 'Disease') :: ['papillomas']

entities_list: @entity14303 :: ('MESH:D008478', 'Disease') :: ['pneumomediastinum']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

answer: @entity5 :: (MESH:D009369,Disease) :: ['benign central airway tumors']


abstract: PURPOSE: The efficacy of three matrix metalloproteinase (MMP) inhibitors with various selectivities ( @entity53278 , @entity65220 , and @entity70248 ) was investigated in a @entity35 model of @entity989 , to examine the roles of @entity33238 in @entity2479 . The susceptibilities of @entity5780 (-/-) and -9(-/-) @entity19 to preretinal neovascularization were investigated in a @entity19 model of @entity26 -induced @entity989 . METHODS: Sprague-Dawley newborn @entity35 were exposed to alternating episodes of 50% and 10% @entity26 (variable @entity26 exposure) to induce @entity2479 . Three MMP inhibitors with various selectivity profiles were administered to variable @entity26 -exposed @entity35 via local or systemic routes. Antineovascular efficacy was determined in drug-treated versus vehicle-treated @entity35 pups by computerized imaging of @entity859 diphosphatase (ADPase)-stained retinal flatmounts. Wild-type C57BL/6J and isogenic @entity5780 (-/-) and -9(-/-) @entity19 were exposed to 75% @entity26 followed by normoxia. The @entity19 were killed immediately before or after the normoxic exposure, and eyes were either harvested for retinal dissection and flatmounting or were paraffin embedded and sectioned. @entity2479 were assessed by @entity859 diphosphatase staining of retinal flatmounts and by counting preretinal nuclei of @entity1710 and @entity1711 -stained retinal sections, respectively. RESULTS: @entity53278 , @entity65220 , and @entity70248 had no effect on normal development of the @entity35 retinal vasculature, regardless of dose or route of administration. Intravitreal injection of @entity53278 (broad-spectrum) immediately after variable- @entity26 exposure and 2 days after exposure resulted in 78% and 82% inhibition of @entity2479 , respectively. @entity65220 ( @entity5780 - and -9-selective inhibitor) and @entity70248 ( @entity5780 -selective inhibitor) resulted in 65% and 52% inhibition, respectively, when administered by intravitreal injection immediately after variable- @entity26 exposure. Intraperitoneal injection of 5, 15, and 50 mg/mL @entity65220 or @entity70248 for 6 days after variable @entity26 exposure resulted in 22% to 39% and 0% to 31% inhibition of neovascularization, respectively. @entity65220 and @entity70248 administered by oral gavage at doses of 3, 10, or 30 mg/mL provided up to 42% and 86% inhibition of neovascularization, respectively. The average vascular areas of retinas from @entity5780 (-/-) or -9(-/-) @entity19 at postnatal day 12 were not significantly different from the wild-type control. There was a 75% (P < 0.001) and 44% (P < 0.01) reduction in preretinal neovascularization in @entity26 -exposed @entity5780 (-/-) and -9(-/-) @entity19 at postnatal day 19, respectively, compared with wild-type control @entity19 . CONCLUSIONS: The results of this study suggest that @entity5780 plays a predominant role in retinal angiogenesis in both the @entity19 and @entity35 models of @entity26 -induced @entity989 . Furthermore, @entity5780 inhibition may be a viable therapeutic approach for @entity2194 characterized by @entity2479 .

title: Pharmacologic and genetic manipulation of MMP-2 and -9 affects XXXX in rodent models of OIR.

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular diseases']

entities_list: @entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine']

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal neovascularization', 'Retinal vascular area and retinal neovascularization']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy', 'retinopathy of prematurity']

answer: @entity2479 :: (MESH:D012173,Disease) :: ['retinal neovascularization']


abstract: @entity23404 of the major salivary gland is a rare condition. We report on a case of bilateral aplasia of the submandibular glands associated with a @entity1002 . A 62-year-old @entity1 came to our department complaining of a 3-year history of left submandibular swelling. She had no notable family or personal medical history. On physical examination of the head and neck region, a 30 mm, non-tender mass was palpated in the left submandibular area. On imaging examinations including ultrasonography and CT, lack of the right submandibular gland and a left submandibular mass with @entity730 were demonstrated. Fine needle aspiration cytology resulted in blood elements only. Functioning tissue could not be observed in the bilateral submandibular glands on @entity1497 scintigraphy. We performed a left submandibular @entity5 extirpation. Intraoperatively, the left submandibular gland and duct were missing. On pathologic examination, the @entity5 was found to be a @entity2695 . The parotid and sublingual glands were recognized bilaterally on postoperative MRI. Her postoperative condition was satisfactory. This condition may be due to the dysfunction of several factors, such as fibroblast growth factors, related to gland differentiation.

title: [A case of bilateral aplasia of the submandibular glands associated with a unilateral submandibular XXXX ].

entities_list: @entity2695 :: ('MESH:D006391', 'Disease') :: ['hemangioma']

entities_list: @entity1497 :: ('MESH:D013670', 'Chemical') :: ['technetium pertechnetate']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification']

entities_list: @entity23404 :: ('MESH:C566720', 'Disease') :: ['Congenital aplasia']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left submandibular hemangioma']

answer: @entity2695 :: (MESH:D006391,Disease) :: ['hemangioma']


abstract: OBJECTIVE: During @entity583 ( @entity583 ), a transient @entity1720 and secretion triggers @entity4854 , which is followed by a substantial increase in mortality. Recent findings in cellular models indicate that HDL may act on @entity413 homeostasis by improving insulin sensitivity and secretion. In this study, we explored this potential effect in @entity1 during the acute phase of @entity583 . METHODS: Plasma @entity413 , insulin and C-peptide were measured at admission in the first 24h and on the fifth day after @entity583 with ST-segment elevation in 183 consecutive non- @entity6 @entity1 . @entity1 were divided into HDL-C quartiles for the analyses (Q1: <31, Q2: 31-38, Q3: 38-47 and Q4: >47mg/dL). The Homeostasis Model Assessment version 2 was used to assess insulin sensitivity (HOMA2S) and beta-cell function (HOMA2B). RESULTS: On admission, no difference was found between the quartiles in @entity413 (p=0.6), insulin (p=0.6) or C-peptide (p=0.5) levels, HOMA2S (p=0.9) or HOMA2B (p=1.0). On the fifth day there was a reduction in @entity413 levels whose intensity was directly proportional to the HDL-C quartile (p<0.001). At the same time, there was a reduction in plasma insulin (p<0.001) and C-peptides (p<0.001) whose magnitude was inversely proportional to the HDL-C quartile. Consistently, the increase of HOMA2S (p<0.001) and HOMA2B (p=0.01) were also positively associated with HDL-C levels. Furthermore, plasma HDL-C levels were inversely and independently associated with blood @entity413 change during the acute phase. CONCLUSION: This study demonstrates the association between low plasma HDL-C levels and increased duration of @entity4854 during @entity583 and suggests in @entity1 the interaction between HDL and insulin secretion and sensitivity.

title: High plasma HDL-C attenuates XXXX during acute phase of @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'humans', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity1720 :: ('MESH:D007333', 'Disease') :: ['decrease of both insulin sensitivity']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['stress hyperglycemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity4854 :: (MESH:D006943,Disease) :: ['stress hyperglycemia']


abstract: @entity1 have significant exposures to @entity5600 , as these chemical plasticizers are ubiquitously present in flexible plastics. Recent epidemiological evidence indicates that @entity1 born to @entity1 exposed to @entity5600 during pregnancy have an increased incidence of @entity154 and @entity409 , signs of a condition referred to as @entity10523 ( @entity10523 ). @entity10523 is thought to develop as a result of environmental factors that cause a testicular disturbance at an early fetal stage with a resultant spectrum of clinical @entity409 , ranging from @entity790 to increased risk for development of @entity5 . Proposed environmental factors in the etiology of @entity10523 include endocrine disrupting compounds such as the @entity5600 . Leydig cells have been classified as one of the main targets for @entity5243 @entity137 in the body based on studies in rodents. In support of this hypothesis, two Leydig cell products - insulin-like growth factor 3 ( @entity32407 ) and @entity251 (T) - are both suppressed after @entity5244 exposures. Both fetal and adult generations of Leydig cells are affected by @entity5243 , although their sensitivities may differ. In rodent models, when pregnant dams are exposed to @entity5243 , fetal Leydig cells form enlarged clusters that are retained in the testis even after birth, in contrast to untreated controls. Despite the retention of fetal Leydig cells, however, their numbers and average cell volume of total in exposed males are reduced, as are @entity32407 production and steroidogenic competence. These alterations are directly associated with clinical features of @entity10523 , including @entity246 and impaired spermatogenesis.

title: @entity5243 XXXX in Leydig cells: developmental timing and dosage considerations.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'boys', 'Humans']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital genital malformations']

entities_list: @entity10523 :: ('MESH:D013733', 'Disease') :: ['TDS', 'testicular dysgenesis syndrome']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['testicular cancer']

entities_list: @entity246 :: ('MESH:D003456', 'Disease') :: ['cryptorchidism']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['spermatogenic dysfunction', 'testicular dysfunction']

entities_list: @entity5244 :: ('MESH:C032279', 'Chemical') :: ['phthalate']

entities_list: @entity5600 :: ('CHEBI:26092', 'Chemical') :: ['phthalates']

entities_list: @entity790 :: ('MESH:D014564', 'Disease') :: ['impaired spermatogenesis and genital malformations']

entities_list: @entity5243 :: ('CHEBI:35484', 'Chemical') :: ['phthalate ester', 'phthalate esters']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: UNASSIGNED: Elderly @entity1 with acute @entity16 are prone to severe disability, @entity1241 ( @entity1241 ), and resultant complications. A @entity262 ( @entity262 ), based on the orthopedic suspension traction system commonly used for conservative treatment of @entity3330 and uncomplicated adult pelvic @entity174 , was developed to facilitate @entity1241 management in @entity1 immobilized secondary to an acute @entity16 . To evaluate the effectiveness and safety of the system, a prospective, randomized, controlled study was conducted between October 2009 and July 2012. Two hundred (200) elderly, bedridden, hospitalized @entity1 with acute, nonchronic @entity16 were randomly assigned to receive routine @entity1241 nursing care (ie, individualized dietary modification, psychological support, health education, and social support for caregivers and family members [control group]) or routine incontinence care plus the @entity262 (experimental group) during the day. Rates of perianal fecal contamination, skin breakdown, incontinenceassociated @entity1909 , pressure ulcer development, and @entity293 ( @entity293 ) were significantly lower in the @entity262 than in the control group (P <0.05). Length of hospitalization and costs of care were also lower in the @entity262 group (P <0.05). @entity1 quality-of-life (QoL) and @entity1241 QoL scores were similar at baseline but significantly higher (better) at the 6-month follow-up interview in the @entity262 than in the control group (P <0.05). In this study, the rate of @entity1241 -associated morbidities was lower and 6-month @entity1 QoL scores were higher in the @entity262 than in the control group. No adverse events were observed, and all @entity1 completed the study. Further clinical studies are needed to examine the long-term effects of @entity262 use among neurologically impaired @entity1241 @entity1 .

title: A Prospective, Randomized, Controlled Study of a Suspension Positioning System Used With Elderly Bedridden XXXX with @entity1241 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment', 'neurological condition']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['suspension positioning system', 'SPS']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['lower urinary tract infection', 'LUTI']

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['FI', 'fecal incontinence']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

entities_list: @entity3330 :: ('MESH:D005264', 'Disease') :: ['pediatric femoral fracture']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The nasal angiocentric T-cell-natural killer cell lymphoma is an aggressive @entity5 , exceptional in Tunisia, which is observed especially in Asia, Mexico and South America. We report the case of an 11-year-old @entity1 , presenting with an exuberant and @entity5 of the right nasal pit. Radiological investigation evidenced a right ethmo  do-frontal @entity5 . Evolution was characterized by the installation of @entity490 and @entity221 , the evidenciation of a mass within the head of the pancreas that compressed the extra hepatic biliary duct and Wirsung's canal and was associated to @entity12828 . Biopsy under ultrasound revealed a histiocytic nature. Nasal biopsy found histiocytic and lymphocytic cells and led to a diagnosis of @entity30558 . The absence of improvement under antibiotic treatment and the development of @entity221 with leuconeutropenia oriented towards the diagnosis of a non-Hodgkinian @entity706 . Medullary biopsy and immunohistochimic study confirmed a T/NK cells lymphoma, with medullary invasion. The @entity1 died from acute @entity649 . The authors insist on the rarity of this bipolar location, in particular in @entity1 , emphasize the difficulty of the diagnosis and review the literature.

title: [Nasal angiocentric T cell-natural killer cell lymphoma with pancreatic localisation in a XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'boy', 'child']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'ulcerative tumor']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress syndrome']

entities_list: @entity30558 :: ('MESH:D012226', 'Disease') :: ['rhinoscleroma']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity12828 :: ('MESH:D034321', 'Disease') :: ['hyperamylasemia']

answer: @entity1 :: (9606,Species) :: ['child']


abstract: PURPOSE: The alpha angle is used to quantify in a single plane the head-neck junction deformity of cam @entity1743 ( @entity1743 ). When the deformity overlaps the superior retinaculum, @entity2738 in this area can jeopardise intra-articular vascular structures. This study proposes a new angular measure of the linear radial extension of @entity85 as a planning tool for bone resection and compares the accuracy of @entity2738 using open and arthroscopic surgery. METHODS: Twenty-five symptomatic @entity1 operated on for @entity1743 were included in this study. Radial magnetic resonance imaging (MRI) was done before and after surgery. Bi-dimensional coordinates of the vascular foramina and radial extension of the deformity (omega angle) were measured. This extension was correlated with the vascular foramina location and alpha-angle value. Accuracy of resection and hip function were evaluated before and after surgery. RESULTS: The cam lesion frequently extended posteriorly. No relation between values of alpha and omega angles was found. Cam resection was complete in 88  % of cases; there was a significant improvement in outcome score after surgery. CONCLUSIONS: This study showed that alpha angle, measured in one plane, was not a predictor of the radial extension of @entity85 . To achieve a full resection, it was frequently necessary to extend the @entity2738 over the retinacular area. Pre-operative determination of the omega angle and location of the vascular foramina helped improve cam resection safety and accuracy.

title: Morphologic and angular planning for cam resection in XXXX : value of the omega angle.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['cam deformity']

entities_list: @entity1743 :: ('MESH:D057925', 'Disease') :: ['femoro-acetabular impingement', 'FAI']

entities_list: @entity2738 :: ('MESH:D005271', 'Disease') :: ['femoral head osteoplasty']

answer: @entity1743 :: (MESH:D057925,Disease) :: ['femoro-acetabular impingement']


abstract: BACKGROUND: @entity75 are occasionally found in the lymphoid or solid organs of @entity1 with common variable @entity465 . OBJECTIVE: To examine the clinical and immunologic conditions in @entity1 with common variable @entity465 who have @entity738 . DESIGN: Case series. SETTING: Large tertiary care medical center. @entity1 : 17 hypogammaglobulinemic @entity1 with common variable @entity465 whose organ or tissue biopsy samples contained noncaseating @entity738 . MEASUREMENTS: Results of lymphocyte function tests. RESULTS: Eight of 17 @entity1 had @entity738 at some point before @entity7893 was diagnosed. Sixteen of the 17 had @entity784 . Although 14 @entity1 received standard treatment with intravenous immunoglobulin, they have had substantial illness, including frequent @entity792 . CONCLUSIONS: Dysregulated T-cell function or macrophage activation may have been involved in formation of @entity738 and @entity101 in hypogammaglobulinemic @entity1 with common variable @entity465 . @entity465 may have contributed to the severity of illness in these @entity1 .

title: @entity738 in common variable XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['increased illness']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Granulomatous lesions']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['deficient T-cell proliferation to mitogens']

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficiency', 'Delay in recognition of antibody deficiency']

entities_list: @entity7893 :: ('MESH:D000361', 'Disease') :: ['hypogammaglobulinemia']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease']

answer: @entity465 :: (MESH:D007153,Disease) :: ['immunodeficiency']


abstract: UNASSIGNED: @entity1398 ( @entity1398 ) are often prescribed to @entity5 @entity1 aiming to reduce @entity281 risk. The goal of this meta-analysis was to determine if @entity1398 indeed reduced the risk of @entity281 and @entity204 in @entity5 @entity1 compared to regular diets (RD). We identified studies in @entity5 @entity1 that compared the effect of @entity1398 vs. RD on the risk of @entity281 and mortality of any cause. The overall effect was calculated by use of a random effects model. Four studies were identified encompassing 918 @entity1 . There was no difference in major @entity281 or mortality rates between @entity1398 and RD groups. When analyzing for the overall composite outcome of any @entity281 or fever, the hazard ratio was significantly higher in the @entity1398 arm (relative risk = 1.18, confidence interval: 1.05 to 1.34, P= 0.007). When the analysis was restricted to only the randomized trials, both groups had a comparable composite outcome. This meta-analysis shows no superiority with respect to mortality or @entity281 of using a neutropenic diet in @entity5 @entity1 . Larger studies are needed that study a broader range of nutritional issues, including the microbiome, in this @entity1 population. Until then, it may be time to relax the restrictions of @entity1398 .

title: The Effect of a Neutropenic Diet on Infection and Mortality Rates in @entity5 XXXX : A Meta-Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['ND', 'Neutropenic diets']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: WHAT IS KNOWN AND OBJECTIVE: @entity573 ( @entity573 ) is an acute self-limiting systemic @entity1333 with specific predilection for the coronary arteries that affects previously healthy young @entity1 and @entity1 . It is the leading cause of childhood-acquired @entity299 in the developed world. Although the stimulus for the cascade of @entity32 in @entity573 is unknown, prompt treatment within 10 days of symptom onset has been shown to improve clinical outcomes and reduce the risk of coronary artery complications. Standard initial therapy is intravenous immunoglobulin (IVIG) and @entity117 . Non-responders to initial therapy remain a challenge. This present review summarizes the treatment options for initial and refractory @entity573 , including the role of @entity230 and other immunosuppressive therapies. METHODS: Literature search using PubMed database to identify pharmacologic studies in @entity573 using the terms @entity573 , intravenous immunoglobulin, refractory, @entity288 , infliximab, @entity205 , @entity1499 , high risk from January 1988-May 2015 was performed. Bibliographies of selected references were also evaluated for relevant articles. Results were limited to those published in English. All articles identified from the PubMed searches were evaluated. RESULTS AND DISCUSSION: Initial IVIG therapy results in rapid resolution of clinical symptoms in 80-90% of @entity1 and has been shown to reduce the risk of @entity301 . Although concomitant @entity117 remains the standard of care for the initial management of @entity573 , the evidence to support its efficacy in improving coronary artery outcomes are lacking. Initial therapy with @entity288 in addition to intravenous immunoglobulin and @entity117 improves outcomes in @entity1 in Japan. However, identifying @entity1 at high risk who may benefit from additional @entity288 in heterogeneous populations has been challenging. Therapeutic options for non-responders to initial therapy are also challenging given the paucity of data. @entity1 who fail to respond to the first dose of IVIG will most often receive a second dose. @entity1 who fail to respond to two doses of IVIG present a unique challenge as the appropriate treatment remains uncertain. Although their effectiveness remains unproven, treatment with infliximab, @entity205 or @entity1499 may be considered in those @entity1 who fail multiple doses of IVIG and @entity230 . WHAT IS NEW AND CONCLUSION: The role of @entity230 in high-risk non-Japanese @entity1 is unclear, with the biggest challenge being early identification of @entity1 at high risk of developing adverse coronary artery outcomes. Limited data evaluating other immunosuppressive agents are available and should be reserved for @entity1 failing two doses of IVIG. Although recent advances in research have broadened our understanding of the epidemiology, genetic susceptibility and pathogenesis of @entity573 , the aetiology of @entity573 remains unclear. Ongoing research will help determine more precise pathogenesis and may assist in developing a diagnostic test as well as identifying new targets for more precise treatment interventions.

title: XXXX : a comprehensive review of treatment options.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'infants']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity573 :: ('MESH:C537014', 'Disease') :: ['KD', 'Kawasaki disease']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity573 :: (MESH:C537014,Disease) :: ['Kawasaki disease']


abstract: Recent experimental evidence underscores the contribution of intestinal bacteria to the inflammatory process of @entity30 . This open study examined the efficacy and safety of combination @entity2177 and @entity868 for @entity1 with active @entity30 and/or colon. Seventy-two @entity1 with active @entity30 (n = 27), ileocolon (n = 22) or colon (n = 23) were treated with @entity2177 500 mg bid and @entity868 250 mg tid for a mean of 10 weeks. Clinical remission was defined as a Harvey-Bradshaw index of three points or less; an index reduction of at least three points indicated a clinical response. Clinical remission was observed in 49 @entity1 (68%), and 55 @entity1 (76%) showed a clinical response. A clinical response was noted in 29 of 43 @entity1 (67%) who were not taking concurrent @entity229 treatment and in 26 of 29 @entity1 (90%) receiving @entity229 (mean dose of 15 mg/day). A clinical response also occurred in a greater proportion of @entity1 with @entity1049 , with or without ileal involvement (84%), compared with @entity1 with @entity4628 alone (64%), and in @entity1 without resection (86%) compared with those with previous resection (61%). Five patients discontinued antibiotics because of adverse events. After a mean follow-up of nine months, clinical remission was maintained in 26 @entity1 off treatment and in 12 @entity1 who continued antibiotic therapy. @entity2177 in combination with @entity868 is well tolerated and appears to play a beneficial role in achieving clinical remission for @entity1 with active @entity30 , particularly when there is involvement of the colon.

title: Combination XXXX and @entity868 for active @entity30 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole']

entities_list: @entity4628 :: ('MESH:D007077', 'Disease') :: ['ileal disease']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity2177 :: ('MESH:D002939', 'Chemical') :: ['Ciprofloxacin', 'ciprofloxacin']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease of the ileum", "Crohn's disease"]

entities_list: @entity1049 :: ('MESH:D003108', 'Disease') :: ['colonic disease']

answer: @entity2177 :: (MESH:D002939,Chemical) :: ['ciprofloxacin']


abstract: @entity1293 -mediated signaling is involved in a variety of functions in @entity1 cells. To determine whether this is true for immunocompetent cells, we generated mutant (Lck- @entity24146 -) @entity19 in which the @entity24146 gene was deleted in a T cell-specific manner using the Cre/loxP system. These @entity19 showed @entity73 cell development. Thymi at most ages were small and their architecture was disorganized. This defect was not due to increased thymocyte apoptosis but to decreased cell proliferation. T cell development was found to be severely arrested at the @entity1961 /CD8 double-negative 3 stage and the thymus contained very few double-positive or single-positive (SP) mature thymocytes. The mutant thymocytes showed impaired proliferative responses to anti- @entity5168 monoclonal antibody (mAb) stimulation or to the cytokines @entity2047 , @entity5003 or @entity2874 . In the spleen, the numbers of mature SP T cells were decreased and their proliferative responses to anti- @entity5168 plus @entity2047 or to anti- @entity10867 mAb were impaired. A severe impairment of @entity5168 -induced expression of @entity3783 was also observed. These data suggest that @entity24146 plays a critical role in the proliferation of thymocytes, which is necessary for early T cell development.

title: T cell-specific gene targeting reveals that XXXX is required for early T cell development.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired early T']

answer: @entity24146 :: (18518(Tax:10090),Gene) :: ['alpha4']


abstract: PURPOSE: We present a series of @entity6369 following a pubovaginal sling procedure due to synthetic and nonsynthetic materials and discuss their management and continence outcome. MATERIALS AND METHODS: During a 3-year period 57 @entity1 underwent urethrolysis for @entity11044 after receiving a pubovaginal sling. @entity6369 , defined as sling material entering the urethral lumen, was present in 9 @entity1 and this cohort comprises the focus of our review. In 3 @entity1 the eroded material was synthetic, that is ProteGen (Boston Scientific, Natick, Massachusetts) in 2 and @entity7502 in 1. This condition was treated with removal of the whole sling, multilayer closure of the erosion and selective use of a Martius flap. In 6 @entity1 the eroded material was nonsynthetic, that is allograft fascia in 5 and autograft fascia in 1. This condition was treated with sling incision and multilayer closure of the urethra. Preoperative assessment included a urogynecologic questionnaire, measurement of pad use, a voiding diary, cystourethroscopy and videourodynamics. Postoperatively similar parameters were used to assess continence outcomes and the need for subsequent procedures. RESULTS: Nine @entity1 were followed 30 months after urethrolysis. All 9 @entity1 had some manifestation of @entity409 following the pubovaginal sling procedure, including urinary retention in 4, urge @entity322 in 3 and mixed @entity322 in 2. Urinary retention resolved in 3 @entity1 and urge @entity322 resolved in 4. @entity3142 ( @entity3142 ) persisted in 2 of the 3 @entity1 in the synthetic group, while no @entity1 in the nonsynthetic group had recurrent @entity3142 . There were no recurrent @entity6369 or @entity292 in either group. CONCLUSIONS: @entity6369 after a pubovaginal sling procedure can occur irrespective of the sling material. However, recurrent @entity3142 is not an invariable outcome of the management of @entity6369 following the pubovaginal sling procedure.

title: XXXX after synthetic and nonsynthetic pubovaginal slings: differences in management and continence outcome.

entities_list: @entity6369 :: ('MESH:D014526', 'Disease') :: ['urethral erosion', 'urethral erosions', 'Urethral erosion']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']

entities_list: @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['voiding dysfunction']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['fistulas']

entities_list: @entity3142 :: ('MESH:D014550', 'Disease') :: ['Stress urinary incontinence', 'SUI']

entities_list: @entity11044 :: ('MESH:D014524', 'Disease') :: ['urethral obstruction']

answer: @entity6369 :: (MESH:D014526,Disease) :: ['Urethral erosion']


abstract: UNASSIGNED: Hemodialysis catheters are vital for @entity177 @entity1 . Permanent tunneled dialysis catheters may be inserted through the jugular, subclavian, and femoral veins. In this paper, we aimed to present the computed tomography findings of a @entity177 @entity1 who had referred our clinic with @entity490 and @entity1353 symptoms. This @entity1 had a formerly inserted hemodialysis catheter for @entity177 and her catheter was found to be extending towards the middle hepatic vein with the tip leaning onto the parenchyma. Hemodialysis catheters can provide instant vascular access and can also be used for the consecutive procedures. Permanent hemodialysis catheters are ideal for long-term use when placing an @entity2548 is contraindicated or is no longer possible under conditions like advanced @entity712 , peripheral @entity455 or short life expectancy. The internal jugular, subclavian, the femoral veins, and the inferior vena cava can be used for catheter insertion. The tip of the catheters inserted in the neck or the thorax must extend to the vena cava superior. Catheter malposition may both lead to fatal outcomes and ineffective dialysis. It is important to obtain chest X-rays after the procedure, particularly to detect catheter malposition.

title: A rare cause of XXXX : Catheter in the middle hepatic vein.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['artery disease']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['chronic renal failure']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity2548 :: ('MESH:D001164', 'Disease') :: ['arteriovenous fistula']

answer: @entity490 :: (MESH:D015746,Disease) :: ['abdominal pain']


abstract: Subcoracoid transfer of the pectoralis major has recently been described as a reconstruction for subscapularis insufficiency. The purpose of this study was to examine the surgically relevant anatomy of this transfer. The importance of understanding this anatomy was recently highlighted to us following our encounter with musculocutaneous neuropraxia in 2 @entity1 after transfer of the entire pectoralis major, one deep to the musculocutaneous nerve. Dissections were performed on 20 fresh, whole @entity1 cadavers in which the entire pectoralis major muscle, medial and lateral pectoral nerves, and musculocutaneous nerve were explored and quantified. The relationship between the pectoralis major and the conjoined tendon was studied in situ and after simulated transfers. The medial and lateral pectoral nerves were located far medial to the pectoralis major tendon insertion and appeared to be safe from injury as long as surgical dissection remained lateral to the pectoris minor and less than 8.5 cm from the humeral insertion. Transfer of the pectoralis major superficial to the musculocutaneous nerve created less @entity5044 . Because proximal innervation of the coracobrachialis and short head of the @entity427 is not an uncommon occurrence, a split pectoralis major transfer, release of the proximal musculocutaneous branches, or debulking of the pectoralis major muscle belly may be required in some instances to prevent @entity2701 on the nerve. Because of the variability and location of the musculocutaneous nerve, it should always be visualized operatively. Transfer of the pectoralis major tendon lateral to the @entity427 tendon appeared to best restore the muscle length- @entity2701 relationship.

title: Anatomic evaluation of the subcoracoid pectoralis major transfer in XXXX cadavers.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity5044 :: ('OMIM:143470', 'Disease') :: ['tension than transfer deep to the musculocutaneous nerve']

answer: @entity1 :: (9606,Species) :: ['human']